- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07400393
Protocollo Comune di Screening MyMatch per l'ALS di Healey (MCSP)
Protocollo Comune di Screening MyMatch ALS (MCSP) di Healey per Determinare l'Eligibilità Preliminare per le Sperimentazioni Cliniche di Fase Precoce MyMatch ALS
The Healey ALS MyMatch Common Screening Protocol (MCSP) is an observational study. The main goal of the study is to help connect adults living with ALS to Healey ALS MyMatch interventional clinical trials that may be a good fit for them.
People who complete an MCSP Screening Visit will undergo:
- clinical assessments
- laboratory testing
- biomarker analyses
The above will be used to determine preliminary eligibility for enrolling ALS MyMatch trials. In addition to helping connect people to a Healey ALS MyMatch interventional clinical trial, the information will also be used to characterize clinical, genetic, and biofluid biomarker profiles. These profiles will help to match the right people to the right trials and evaluate the frequency of ALS-associated gene variants. Blood samples and DNA will also be stored for future ALS and biomarker research.
Panoramica dello studio
Stato
Descrizione dettagliata
The MyMatch Common Screening Protocol (MCSP) is an observational study that is part of the Healey ALS MyMatch program. Healey ALS MyMatch is an early phase (Phase 1b or 2a), Amyotrophic Lateral Sclerosis (ALS) clinical trial program. ALS MyMatch is designed to help match adults living with ALS to Healey ALS MyMatch interventional clinical trials that may be a good fit for them.
The first step in participating in Healey ALS MyMatch is to complete a screening visit for the MCSP. MCSP screening visit activities can be completed over a period of 45-days and some screening visit activities can be completed remotely. MCSP screening visit activities include:
- obtaining informed consent
- reviewing medical history
- collecting blood samples
- completing a 12-lead ECG
- completing questionnaires
To be eligible to participate in the MCSP, the following key criteria will need to be met: ALS diagnosis, SVC breathing score of equal to or greater than 65%, and ALS genetic testing.
The information collected at the MCSP screening visit helps researchers determine whether a participant might qualify for one or more treatment studies that are currently enrolling in the ALS MyMatch program. If a participant appears eligible for more than one study, then the participant may choose to consult with their doctor and decide which study would be a better fit for them.
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: Healey ALS MyMatch Clinical Operations Team
- Numero di telefono: 857-282-9210
- Email: mghalsmymatch@mgb.org
Luoghi di studio
-
-
Florida
-
Davie, Florida, Stati Uniti, 33314
- Non ancora reclutamento
- Nova Southeastern University
-
Contatto:
- Donovan Mott
- Numero di telefono: 954-203-2829
- Email: Donovan.mott@nova.edu
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60611
- Non ancora reclutamento
- Northwestern University
-
Contatto:
- Candace James
- Numero di telefono: 312-503-0747
- Email: candace.james@northwestern.edu
-
Contatto:
- ALS Research
- Email: alsresearch@northwestern.edu
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02114
- Reclutamento
- Massachusetts General Hospital
-
Contatto:
- Hattie Grant
- Numero di telefono: 617-643-7912
- Email: healeysitemymatchmgh@mgb.org
-
-
Minnesota
-
Minneapolis, Minnesota, Stati Uniti, 55414
- Non ancora reclutamento
- University of Minnesota
-
Contatto:
- Tori Schirrick
- Numero di telefono: (612) 626-7300
- Email: kaste125@umn.edu
-
Contatto:
- Julia Munoz
- Numero di telefono: (612)-624-9987
- Email: munoz156@umn.edu
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
The target populations for MCSP and ALS MyMatch trials will initially focus on subgroups of individuals with ALS, including those with early-stage disease. Some ALS MyMatch trials will further target those with specific biomarkers or genetic markers for inclusion in a specific trial.
Descrizione
Inclusion Criteria:
- Ability to provide written informed consent.
- Adults > 18 years of age.
- Diagnosis of symptomatic ALS that meets either the revised El Escorial Criteria.(clinically possible, probable, probable lab-supported, or definite) or the Gold Coast Criteria.
- Available or pending clinically obtained CLIA ALS genetic panel report.
- Time since onset of weakness due to ALS ≤ 24 months at the time of MCSP screening.
- Slow VC ≥ 65% of predicted capacity value for gender, height and age at screening.
- Clinically unremarkable Complete Blood Counts as per SI's discretion, including but not limited to Hemoglobin ≥ 9 g/dL.
- Ability and willingness to complete all study procedures per SI's assessment.
- Negative pregnancy test at screening for women of child-bearing potential (WOCB), defined as a sexually mature woman who has not undergone a hysterectomy or who has not been naturally postmenopausal for at least 24 consecutive months (i.e., who has had menses any time in the preceding 24 consecutive months).
Exclusion Criteria:
-
Clinically significant unstable medical or surgical condition that would pose a risk to the participant's trial procedural participation or interfere with data collection, per SI's assessment.
-
Presence of cognitive or mental health disorders impairing ability to provide informed consent for the study per SI assessment.
-
Active cancer or history of cancer, unless it was successfully treated for durable remission or cure more than 3 years ago. (Note that basal cell carcinoma, squamous cell carcinoma in situ, cervical carcinoma in situ, prostatic carcinoma in situ, or other malignancies that have been curatively excised at any time previously and with no evidence of disease recurrence for at least 3 years are not exclusionary.)
-
Prior solid organ transplantation.
-
Use of investigational treatments for ALS (off-label use or active participation in a clinical trial) within 5 half-lives (if known) or 30 days (whichever is longer) prior to the MCSP Screening Visit. (Please refer to the Manual of Procedures (MOP) for current list of experimental therapies)
-
Screening 12-lead ECG showing QT interval corrected for rate (QTcF) > 470 msec for women and > 450 msec for men, absence of second degree or higher AV block or other clinically significant cardiac arrythmias.
-
Clinically significant abnormalities in the Comprehensive Metabolic Panel per SI's assessment, including but not limited to:
- Serum alanine aminotransferase or aspartate aminotransferase > 3 times the upper limit of normal, or serum bilirubin > 1.5 × upper limit of normal
- Estimated GFR (eGFR) of < 30 mL/min/1.73m2
-
Other clinically significant electrolyte and metabolic abnormalities
-
If female, breastfeeding, pregnant, or of child-bearing potential and unwilling to use effective contraception for duration of the trial and after discontinuing treatment as outlined in the ALS MyMatch trial protocol.
-
Clinically significant unstable medical conditions (other than ALS) that would pose a risk to the participant, per SI's assessment (e.g., cardiovascular instability, systemic infection,), or clinically significant laboratory abnormality or ECG changes.
-
Exposure at any time to any gene therapies under investigation for the treatment of ALS (off-label use or investigational).
-
Participants who require Permanent assisted ventilation (PAV). PAV defined as more than 22 hours per day of noninvasive or invasive mechanical ventilation for more than seven consecutive days. The date of onset of PAV is the first day of the seven days.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Preliminary eligibility to be matched to a MyMatch Trial
Lasso di tempo: From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial.
|
To determine preliminary eligibility of early ALS (< 24 months from weakness onset) participants for actively enrolling ALS MyMatch trial(s) |
From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial.
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Repository for future research
Lasso di tempo: From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial. Samples will be banked indefinitely for future research on ALS and related diseases.
|
To build an ALS biofluid, genetic and data repository for future clinical and translational research. |
From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial. Samples will be banked indefinitely for future research on ALS and related diseases.
|
|
Prevalence of gene mutations
Lasso di tempo: From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial. Samples will be banked indefinitely for future research on ALS and related diseases.
|
To characterize the prevalence of participants with causative or risk modifier gene mutations in the MCSP |
From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial. Samples will be banked indefinitely for future research on ALS and related diseases.
|
|
Collect and bank samples
Lasso di tempo: From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial. Samples will be banked indefinitely for future research on ALS and related diseases.
|
To collect and bank blood samples for future biofluid biomarker analyses |
From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial. Samples will be banked indefinitely for future research on ALS and related diseases.
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie del sistema nervoso centrale
- Malattie del sistema nervoso
- Malattie neuromuscolari
- Malattie metaboliche
- Malattie Neurodegenerative
- Malattie del midollo spinale
- TDP-43 Proteinopatie
- Carenze di proteostasi
- Malattia del motoneurone
- Malattie nutrizionali e metaboliche
- Sclerosi laterale amiotrofica
Altri numeri di identificazione dello studio
- 2025P002080
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .